Antitrust delay scuppers Novartis’ $1bn generics sale to AurobindoNovartis has called off the sale of two US generics businesses to India’s Aurobindo Pharma, part of a Share XAntitrust delay scuppers Novartis’ $1bn generics sale to Aurobindohttps://pharmaphorum.com/news/antitrust-delay-scuppers-novartis-1bn-generics-sale-to-aurobindo/
Sanofi to combat shortages with European medicines ingredient firmSanofi is to create a European company focused on production and marketing of active pharmaceutical ingredients (API) – Share XSanofi to combat shortages with European medicines ingredient firmhttps://pharmaphorum.com/news/sanofi-to-combat-shortages-with-european-medicines-ingredient-firm/
